CARM vs. CRVS, CUE, RLYB, IMMX, CELU, MNOV, LABP, TPST, MRNS, and ASRT
Should you be buying Carisma Therapeutics stock or one of its competitors? The main competitors of Carisma Therapeutics include Corvus Pharmaceuticals (CRVS), Cue Biopharma (CUE), Rallybio (RLYB), Immix Biopharma (IMMX), Celularity (CELU), MediciNova (MNOV), Landos Biopharma (LABP), Tempest Therapeutics (TPST), Marinus Pharmaceuticals (MRNS), and Assertio (ASRT). These companies are all part of the "pharmaceutical preparations" industry.
Carisma Therapeutics (NASDAQ:CARM) and Corvus Pharmaceuticals (NASDAQ:CRVS) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, community ranking, risk, valuation, analyst recommendations, dividends, earnings and profitability.
44.3% of Carisma Therapeutics shares are owned by institutional investors. Comparatively, 46.6% of Corvus Pharmaceuticals shares are owned by institutional investors. 17.0% of Carisma Therapeutics shares are owned by insiders. Comparatively, 31.3% of Corvus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Carisma Therapeutics currently has a consensus price target of $8.80, suggesting a potential upside of 370.59%. Corvus Pharmaceuticals has a consensus price target of $6.63, suggesting a potential upside of 360.07%. Given Carisma Therapeutics' stronger consensus rating and higher possible upside, research analysts plainly believe Carisma Therapeutics is more favorable than Corvus Pharmaceuticals.
Corvus Pharmaceuticals has lower revenue, but higher earnings than Carisma Therapeutics. Corvus Pharmaceuticals is trading at a lower price-to-earnings ratio than Carisma Therapeutics, indicating that it is currently the more affordable of the two stocks.
Corvus Pharmaceuticals received 275 more outperform votes than Carisma Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Carisma Therapeutics an outperform vote while only 62.23% of users gave Corvus Pharmaceuticals an outperform vote.
In the previous week, Corvus Pharmaceuticals had 3 more articles in the media than Carisma Therapeutics. MarketBeat recorded 4 mentions for Corvus Pharmaceuticals and 1 mentions for Carisma Therapeutics. Corvus Pharmaceuticals' average media sentiment score of 1.11 beat Carisma Therapeutics' score of 0.00 indicating that Corvus Pharmaceuticals is being referred to more favorably in the news media.
Corvus Pharmaceuticals has a net margin of 0.00% compared to Carisma Therapeutics' net margin of -582.34%. Corvus Pharmaceuticals' return on equity of -59.63% beat Carisma Therapeutics' return on equity.
Carisma Therapeutics has a beta of 0.95, suggesting that its stock price is 5% less volatile than the S&P 500. Comparatively, Corvus Pharmaceuticals has a beta of 1.03, suggesting that its stock price is 3% more volatile than the S&P 500.
Summary
Corvus Pharmaceuticals beats Carisma Therapeutics on 11 of the 17 factors compared between the two stocks.
Get Carisma Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for CARM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding CARM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Carisma Therapeutics Competitors List
Related Companies and Tools
